Annalise.ai vs Qure AI
Both are FDA cleared, comprehensive readers of chest X-ray and head CT deployed at national scale, both grade A on AI centrality and specialty coverage, so the split is finding count breadth and reimbursement against regulatory depth and model discipline. If your priority is the widest coverage per study plus a defined Medicare path and time critical triage routing, start with Annalise.ai. If your failure mode is deploying a chest X-ray model that drifts silently after clearance, start with Qure AI, the only chest X-ray CADe cleared with a Predetermined Change Control Plan and the deeper validation record. Annalise reads up to 124 findings on chest X-ray and 130 on head CT in one pass. Qure holds 26 FDA cleared indications, the deepest regulatory footprint in the index.
- The widest coverage per study: up to 124 findings on chest X-ray and 130 on head CT in a single pass, against Qure's approach of separately cleared indications.
- A defined US reimbursement path: Medicare New Technology Add on Payment status, which changes the return calculation for a hospital buyer in a way almost no imaging vendor here can point to.
- Triage strength: the highest number of cleared triage findings on chest X-ray, the first Breakthrough Device Designation ever granted to a radiology triage device, and unique differentiation of tension pneumothorax for the most urgent routing.
- The deepest regulatory record in the index, 26 FDA cleared indications across nine products, and the only chest X-ray CADe cleared with a Predetermined Change Control Plan, so model updates follow a path agreed with the FDA rather than arriving silently.
- A stronger validation posture: the latest clearance rested on both a standalone performance test and a multi reader multi case study, the higher evidentiary bar for imaging AI.
- Built for non radiologist readers too, with cleared use by emergency and family medicine physicians, useful where a radiologist is not first to the film.
Side-by-Side
| Axis | A Annalise.ai |
Q Qure AI |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Both are assistive with the radiologist reading every study, both are FDA cleared and deployed across more than 40 countries, and neither publishes a security attestation, data residency terms, or demographic subgroup analysis, which matters because chest X-ray AI performance is known to vary with acquisition equipment and patient demographics. Annalise's headline 32 percent head CT accuracy improvement lacks published study detail, and its evidence leans on deployment scale rather than peer reviewed outcomes. Qure withholds pricing and any named PACS integration. Both are headquartered outside the US, Qure in India and Annalise an Australian joint venture, so a US buyer should establish business associate terms and confirm where inference runs.